Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 10/20 | 0.60 |
| ▸ | POLB | P06746 | 1/20 | 0.59 |
| ▸ | MEN1 | O00255 | 3/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.53 |
| ▸ | USP2 | O75604 | 1/20 | 0.53 |
| ▸ | RAB9A | P51151 | 2/20 | 0.50 |
| ▸ | HTT | P42858 | 1/20 | 0.50 |
| ▸ | NPC1 | O15118 | 1/20 | 0.50 |
| ▸ | CDK2 | P24941 | 1/20 | 0.49 |
| ▸ | FLT4 | P35916 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 1/20 | 0.49 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1420825 | 0.82 | EPHX2 (0.68) | EPHX2KMT2ARAB9A | |
| SCHEMBL19808689 | 0.81 | POLB (0.51) | EPHX2POLBMEN1KMT2AUSP2 | |
| SCHEMBL9637653 | 0.77 | MEN1 (0.77) | MEN1KMT2ARAB9AHTTNPC1 | |
| SCHEMBL30051982 | 0.77 | MEN1 (0.77) | MEN1KMT2ARAB9AHTTNPC1 | |
| SCHEMBL4115733 | 0.75 | EPHX2 (0.70) | EPHX2POLBMEN1KMT2ARAB9A | |
| SCHEMBL18028552 | 0.75 | CYP1A2 (0.56) | EPHX2 | |
| Hydrochloric Acid SCHEMBL29388210 | 0.75 | MEN1 (0.74) | MEN1KMT2ARAB9AHTTNPC1 | |
| Bromide SCHEMBL29417998 | 0.75 | MEN1 (0.74) | MEN1KMT2ARAB9AHTTNPC1 | |
| SCHEMBL4112211 | 0.74 | EPHX2 (0.64) | EPHX2MEN1KMT2ARAB9ANPC1 | |
| SCHEMBL4112779 | 0.74 | EPHX2 (1.00) | EPHX2MEN1KMT2ARAB9ANPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10202388-B2 | Fused-ring compounds, pharmaceutical composition and uses thereof | Shanghai De Novo Pharmatech Co., Ltd. (CN) | 2019-02-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10202388-B2 | Fused-ring compounds, pharmaceutical composition and uses thereof | IDO1, IDO2, TDO2 | EPHX2 1124/4885POLB 3403/4885MEN1 1504/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.